Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.46 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97114 | 0.98 | ALDH1A1 (0.52) | ALDH1A1CYP2A6PIM1PIM2EPHX2 | |
| Formaldehyde SCHEMBL28016257 | 0.94 | ALDH1A1 (0.48) | ALDH1A1CYP2A6PIM1PIM2EPHX2 | |
| Ethylene SCHEMBL27779893 | 0.94 | ALDH1A1 (0.48) | ALDH1A1CYP2A6PIM1PIM2EPHX2 | |
| SCHEMBL1744566 | 0.92 | PARP10 (0.50) | ALDH1A1CYP2A6PIM1PIM2EPHX2 | |
| SCHEMBL3464472 | 0.92 | CYP2D6 (0.48) | ALDH1A1CYP2A6PIM1PIM2EPHX2 | |
| SCHEMBL505301 | 0.92 | DRD1 (0.56) | ALDH1A1CYP2A6PIM1PIM2EPHX2 | |
| SCHEMBL3464474 | 0.92 | CYP2D6 (0.48) | ALDH1A1CYP2A6PIM1PIM2EPHX2 | |
| SCHEMBL27556434 | 0.88 | STS (0.47) | ALDH1A1CYP2A6PIM1PIM2EPHX2 | |
| SCHEMBL9607433 | 0.88 | ALDH1A1 (0.49) | ALDH1A1CYP2A6PIM1PIM2EPHX2 | |
| SCHEMBL24512622 | 0.87 | PIM1 (0.43) | ALDH1A1CYP2A6PIM1PIM2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| CN-118005608-A | Triazole small molecular organic compound for inhibiting mitochondrial oxidative phosphorylation by specific targeting complex I and application thereof | 华东师范大学 | 2024-05-10 | — | — | CN | disclosed |
| US-7683070-B2 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | FMC CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| CN-101426792-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT GMBH & CO KG (DE) | 2009-05-06 | — | — | CN | disclosed |
| US-20080090828-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | BAYER CROPSCIENCE AG (DE) | 2008-04-17 | — | — | US | disclosed |
| US-7300946-B2 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | BAYER CROPSCIENCE AG (DE) | 2007-11-27 | — | — | US | disclosed |
| EP-1572207-A4 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL) PIPERIDINES AND PYRIDINES | FMC CORP (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060135504-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | FMC CORPORATION | 2006-06-22 | — | — | US | disclosed |
| EP-1572207-A1 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL) PIPERIDINES AND PYRIDINES | FMC CORPORATION (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004060371-A1 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL) PIPERIDINES AND PYRIDINES | FMC CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135504-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | DDT, DRD4, QDPR | DRD1 4/4885GAA 4520/4885ALDH1A1 1706/4885 |
| US-20080090828-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | DDT, DRD4, QDPR | DRD1 4/4885GAA 4569/4885ALDH1A1 1757/4885 |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | DRD1 3524/4885GAA 4701/4885ALDH1A1 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.